Kinnate Biopharma Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Kinnate Biopharma Inc. | KNTE - NASDAQ |
$18.00-$19.00 | $20.00 | $40.00 | 12 million | 12/3/2020 |
| Goldman Sachs, SVB Leerink , Piper Sandler | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-11-13 Terms Added 2020-11-30 Amended Terms 2020-12-02 | ||||||
Kinnate Biopharma Inc. Quote & Chart - Click for current quote - KNTE
IPO Boutique aggregates information on public companies and private companies, such as "KNTE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Kinnate Biopharma Inc. (adapted from Kinnate Biopharma Inc. prospectus):
They are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "KNTE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.